title: [Metabolic radiotherapy for gastroenteropancreatic endocrine tumors using radiolabeled somatostatin].
abstract: Surgery is the only curative treatment of gastro-entero-pancreatic endocrine tumors. In inoperable or metastasized forms, therapeutic options are limited. The metabolic or systemic radiotherapy, using radiolabeled somatostatin analogs, constitutes a new therapeutic alternative, currently in development which requires the presence of high affinity somatostatin receptors on tumoral cells. Using (111)In-pentetreotide, the main result is a symptomatic effect. With new somatostatin analogs coupled to B- emitters, such as Octreother or (177)Lu-DOTA-Octreotate, 10 to 30% of objective tumoral responses are observed in progressive patients, unresponsive to conventional treatments. Such results are explained by the high affinity for somatostatin receptors and the large emission diameter of these radiolabeled compounds. Renal toxicity is limited by amino-acid infusion whereas changes in blood count are usually moderate and transient. Multicentric prospective studies are necessary to identify the predictive factors of tumoral response and toxicity. The prospects are related to the development of new radiopharmaceuticals, even more specific of somatostatin receptors sub-types and to the use of other peptide analogues whose applications will overflow the framework of endocrine tumours.
authors.affiliation: Fédération d'endocrinologie et Centre de Médecine Nucléaire, Groupement Hospitalier Est, 59, boulevard Pinel, 69677 Bron cedex. francoise.borson-chazot@chu-lyon.fr
authors.forename: F
authors.initials: F
authors.lastname: Borson-Chazot
mesh_terms: D006727:Hormone Antagonists / Q000627:therapeutic use*; D006801:Humans; D007414:Intestinal Neoplasms / Q000532:radiotherapy*; D015282:Octreotide / Q000031:analogs & derivatives / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000532:radiotherapy*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000532:radiotherapy*
chemical_list: C504257:177Lu-octreotide, DOTA(0)-Tyr(3)-; D006727:Hormone Antagonists; D019275:Radiopharmaceuticals; D013004:Somatostatin; C496730:90Y-octreotide, DOTA-Tyr(3)-; C081788:pentetreotide; D015282:Octreotide